Patents by Inventor Yat Sun Or

Yat Sun Or has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIVIRAL HETEROCYCLIC COMPOUNDS
    Publication number: 20230115580
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: April 13, 2022
    Publication date: April 13, 2023
    Inventors: Adam Szymaniak, Jianming Yu, Kevin McGrath, Xiben Li, Tyler J. Mann, Robert Leon, In Jong Kim, Yat Sun Or, Long Nguyen
  • NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS
    Publication number: 20230103494
    Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 22, 2021
    Publication date: April 6, 2023
    Inventors: Guoqiang Wang, Ruichao Shen, Yong He, Jun Ma, Xuechao Xing, Hui Cao, Xuri Gao, Xiaowen Peng, Jiang Long, Wei Li, Jiajun Zhang, Joseph D. Panarese, Nathaniel Thomas Kenton, Samuel Bartlett, Yat Sun Or
  • ANTIVIRAL HETEROCYCLIC COMPOUNDS
    Publication number: 20230108803
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: February 24, 2022
    Publication date: April 6, 2023
    Inventors: Adam Szymaniak, Jianming Yu, Kevin McGRATH, Xiben Li, Tyler J. Mann, Robert Leon, In Jong Kim, Yat Sun Or, Long Nguyen
  • BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS
    Publication number: 20230087410
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: May 3, 2022
    Publication date: March 23, 2023
    Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph D. Panarese, Yat Sun Or
  • FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS
    Publication number: 20230075366
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: November 3, 2021
    Publication date: March 9, 2023
    Inventors: Joseph Panarese, Dexter Davis, Samuel Bartlett, Katherine Chong, Nathaniel Kenton, Yat Sun Or
  • Hepatitis B antiviral agents
    Patent number: 11596611
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: March 7, 2023
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yao-Ling Qiu, Xuri Gao, Jorden Kass, Hui Cao, Wei Li, Xiaowen Peng, Byung-Chul Suh, Yat Sun Or
  • Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
    Patent number: 11578097
    Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: February 14, 2023
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, Jing He, Guoqiang Wang
  • Antiviral heterocyclic compounds
    Patent number: 11572367
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: July 16, 2020
    Date of Patent: February 7, 2023
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Adam Szymaniak, Kevin McGrath, Jianming Yu, Tyler Mann, Long Nguyen, Kaicheng Zhu, In Jong Kim, Yat Sun Or
  • Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
    Patent number: 11560368
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: January 24, 2023
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Ruichao Shen, Jiang Long, Jun Ma, Xuechao Xing, Yong He, Brett Granger, Jing He, Bin Wang, Yat Sun Or
  • Isoxazole derivatives as FXR agonists and methods of use thereof
    Patent number: 11555032
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: January 17, 2023
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Jun Ma, Bin Wang, Ruichao Shen, Xuechao Xing, Yong He, Yat Sun Or
  • Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
    Patent number: 11534439
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: December 27, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Jianming Yu, In Jong Kim, Yat Sun Or
  • BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF
    Publication number: 20220402966
    Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Application
    Filed: May 19, 2021
    Publication date: December 22, 2022
    Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Xuechao Xing, Jiang Long, Peng Dai, Brett Granger, Jing He
  • NOVEL MACROCYCLIC SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS
    Publication number: 20220402926
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 13, 2022
    Publication date: December 22, 2022
    Inventors: Jiajun Zhang, Xiaowen Peng, Byung-Chul Suh, Jorden Kass, Xuri Gao, Hui Cao, Wei Li, Joseph D. Panarese, Guoqiang Wang, Yat Sun Or
  • NOVEL MACROCYCLIC ANTIVIRAL AGENTS
    Publication number: 20220380377
    Abstract: The present invention discloses macrocyclic compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 3, 2022
    Publication date: December 1, 2022
    Inventors: Jiajun Zhang, Xiaowen Peng, Yat Sun Or
  • Antiviral heterocyclic compounds
    Patent number: 11505558
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: April 1, 2021
    Date of Patent: November 22, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Adam Szymaniak, Kevin McGrath, Jianming Yu, Tyler Mann, Long Nguyen, Kaicheng Zhu, In Jong Kim, Yat Sun Or
  • APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20220356167
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Application
    Filed: March 10, 2021
    Publication date: November 10, 2022
    Inventors: Guoqiang Wang, Ruichao Shen, Jiang Long, Jun Ma, Xuechao Xing, Yong He, Brett Granger, Jing He, Bin Wang, Yat Sun Or
  • ANTIVIRAL HETEROCYCLIC COMPOUNDS
    Publication number: 20220356189
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: July 16, 2020
    Publication date: November 10, 2022
    Inventors: Adam Szymaniak, Kevin McGrath, Jianming Yu, Tyler Mann, Long Nguyen, Kaicheng Zhu, In Jong Kim, Yat Sun Or
  • EIF4E INHIBITORS AND USES THEREOF
    Publication number: 20220356178
    Abstract: The present invention provides compounds inhibiting eIF4E activity, and compositions and methods of using thereof.
    Type: Application
    Filed: March 3, 2021
    Publication date: November 10, 2022
    Inventors: Christopher L. VANDEUSEN, Alan E. WALTS, Yat Sun OR
  • Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
    Patent number: 11472808
    Abstract: The present invention discloses substituted pyrrolo[1,2-c]pyrimidines, such as the compound which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: October 18, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yao-Ling Qiu, Xiaowen Peng, Wei Li, Xuri Gao, Jorden Kass, Byung-Chul Suh, Hui Cao, Jiajun Zhang, Yat Sun Or
  • COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS
    Publication number: 20220323460
    Abstract: The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.
    Type: Application
    Filed: November 10, 2020
    Publication date: October 13, 2022
    Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph Panarese, Kai Lin, Michael H.J. Rhodin, Nicole V. McAllister, Yat Sun Or